BIOPHYTIS NAM. EO -,80 (6XB3.BE)
| Previous Close | 0.6390 |
| Open | 0.6340 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.6340 - 0.6340 |
| 52 Week Range | 0.0400 - 8.6000 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, ...
- ACCESSWIRE
Combined General Meeting of June 24, 2024
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, ...
- ACCESSWIRE
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, ...
